Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial
20 oct. 2021 07h00 HE
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK – 20 October...
Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial
28 mai 2020 07h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial Southampton, UK – 28 May 2020: Synairgen plc (LSE: SNG), the...